Altay Aliyev

Dr. Altay Aliyev is a specialist in internal medicine and medical oncology at Liv Bona Dea Hospital Baku. He completed a research residency at the Cleveland Clinic in the United States. Dr. Aliyev focuses on the early diagnosis, immunotherapy, and targeted treatment of solid tumors.

Specialization and Clinical Focus

Dr. Aliyev treats oncological conditions using modern systemic therapies. He specializes in creating treatment plans for breast, colon, and prostate cancers. The physician also treats rare malignancies like chordoma, thymoma, and glioblastoma. These therapies include:

• Cytotoxic chemotherapy and hormone therapy
• Molecularly targeted treatments for metastatic disease
• Cancer immunotherapy and palliative care
• Treatment of side effects, such as chemotherapy-related arterial issues
• Early cancer diagnosis and prevention strategies

Professional Experience

• Currently serves as a medical oncologist at Liv Bona Dea Hospital Baku.
• 2016–2019 — Specialist in medical oncology at Bezmiâlem Foundation University.
• 2013–2014 — Research Associate at the Cleveland Clinic Endocrinology Department.
• 2011–2015 — Internal medicine specialist at Istanbul University, Istanbul Faculty of Medicine.

Education and Academic Background

• 2004–2010 — Istanbul University, Istanbul Faculty of Medicine — Degree in medicine.
• 2015 — Internal Medicine Specialty, Istanbul Faculty of Medicine.
• 2019 — Medical Oncology Subspecialty, Bezmiâlem Foundation University.

Research and Scientific Contributions

The doctor conducts research on tumor markers and treatment outcomes. He investigated the prognostic value of monocyte counts in mantle cell lymphoma. His research also covers the effects of chemotherapy on lipid profiles and anthropometric parameters. Dr. Aliyev has published over five original studies in international medical journals. These publications include:

• "The utility of peripheral thyrotropin receptor mRNA in the management of differentiated thyroid cancer."
• "Diagnostic accuracy of circulating thyrotropin receptor messenger RNA in thyroid cytology," published in Surgery.
• "Role of Urotensin-2 in 5-Fluorouracil-Related Arterial Vasoconstriction in Cancer Patients."
• "Real-life practice outcomes of Pertuzumab and Trastuzumab-based treatment for breast cancer."
• "Usefulness of serum M30 and M65 levels to predict chemotherapy response."
• "Circulating Thyroid-Stimulating Hormone Receptor Messenger RNA as a Marker of Tumor Aggressiveness in Patients with Papillary Thyroid Microcarcinoma."
• "Prognostic impact of primary tumor location on survival in metastatic colorectal cancer patients: A single center experience."